ES462699A1 - Process for the isolation of a placentaspecificglycoprotein - Google Patents

Process for the isolation of a placentaspecificglycoprotein

Info

Publication number
ES462699A1
ES462699A1 ES462699A ES462699A ES462699A1 ES 462699 A1 ES462699 A1 ES 462699A1 ES 462699 A ES462699 A ES 462699A ES 462699 A ES462699 A ES 462699A ES 462699 A1 ES462699 A1 ES 462699A1
Authority
ES
Spain
Prior art keywords
support
bound
order
solution
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES462699A
Other languages
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of ES462699A1 publication Critical patent/ES462699A1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

In order to concentrate the placenta-specific protein PP5, a PP5-containing protein solution is brought into contact, at a pH of between 4 and 9, with an antibody against PP5 which is bound to an insoluble support. The support with the PP5 bound to it is separated off from the liquid phase. In order to release the PP5, this support is treated with an aqueous medium of a pH of from 2 to 4, or with a solution of a substance which dissociates protein bonds at a pH of from 4 to 9. The PP5 which is obtained can be used in a diagnostic agent for detecting PP5 and antibodies directed against PP5.
ES462699A 1976-04-17 1977-09-28 Process for the isolation of a placentaspecificglycoprotein Expired ES462699A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2616984A DE2616984C3 (en) 1976-04-17 1976-04-17 Method for the isolation and purification of a placenta-specific glycoprotein

Publications (1)

Publication Number Publication Date
ES462699A1 true ES462699A1 (en) 1978-07-01

Family

ID=5975638

Family Applications (2)

Application Number Title Priority Date Filing Date
ES457714A Expired ES457714A1 (en) 1976-04-17 1977-04-12 Process for the isolation of a placentaspecificglycoprotein
ES462699A Expired ES462699A1 (en) 1976-04-17 1977-09-28 Process for the isolation of a placentaspecificglycoprotein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES457714A Expired ES457714A1 (en) 1976-04-17 1977-04-12 Process for the isolation of a placentaspecificglycoprotein

Country Status (20)

Country Link
JP (1) JPS52154509A (en)
AT (1) AT362057B (en)
AU (1) AU517434B2 (en)
BE (1) BE853711A (en)
CA (1) CA1101847A (en)
CH (2) CH630643A5 (en)
DE (1) DE2616984C3 (en)
DK (1) DK168577A (en)
ES (2) ES457714A1 (en)
FI (1) FI60875C (en)
FR (1) FR2348222A1 (en)
GB (1) GB1555197A (en)
IE (1) IE44824B1 (en)
IL (1) IL51883A (en)
IT (1) IT1075832B (en)
LU (1) LU77143A1 (en)
NL (1) NL7703963A (en)
NO (1) NO146747C (en)
NZ (1) NZ183878A (en)
SE (1) SE7704359L (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2640387C3 (en) * 1976-09-08 1981-01-22 Behringwerke Ag, 3550 Marburg Tissue-specific protein and method for its production
DE2720704C2 (en) * 1977-05-07 1986-09-25 Behringwerke Ag, 3550 Marburg New glycoprotein, process for its production and its uses
DE2745680A1 (en) * 1977-10-11 1979-04-12 Behringwerke Ag CONTRACEPTIVE MEANS
EP0029893B1 (en) * 1979-11-02 1987-05-20 Karl Prof. Dr. Theurer Process for concentration of tumor-inhibiting substances
DE3013724A1 (en) 1980-04-10 1981-10-15 Behringwerke Ag, 3550 Marburg NEW PROTEIN PP (DOWN ARROW) 9 (DOWN ARROW), METHOD FOR ITS ENRICHMENT AND PRODUCTION AND ITS USE
DE3334405A1 (en) * 1983-09-23 1985-04-04 Behringwerke Ag, 3550 Marburg MEMBRANE ASSOCIATED PROTEINS (MP (DOWN ARROW) 2 (DOWN ARROW)), METHOD FOR THEIR EXTRACTION AND USE
NZ212523A (en) * 1985-06-24 1989-01-06 Univ Massey Mobile phase for purification of proteins by high performance liquid chromatography
US5968477A (en) 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
CA2190727C (en) * 1994-05-19 2006-07-18 Sudhakar Kasina Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging
US6005083A (en) 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms

Also Published As

Publication number Publication date
AU2431977A (en) 1978-10-19
ATA266377A (en) 1980-09-15
NZ183878A (en) 1980-04-28
IL51883A (en) 1980-02-29
NO771316L (en) 1977-10-18
JPS52154509A (en) 1977-12-22
NO146747C (en) 1982-12-01
FR2348222B1 (en) 1980-02-08
LU77143A1 (en) 1977-11-14
SE7704359L (en) 1977-10-18
NL7703963A (en) 1977-10-19
AT362057B (en) 1981-04-27
ES457714A1 (en) 1978-02-16
AU517434B2 (en) 1981-07-30
IE44824B1 (en) 1982-04-07
DE2616984C3 (en) 1981-10-29
DE2616984B2 (en) 1981-01-29
FI771186A (en) 1977-10-18
GB1555197A (en) 1979-11-07
FI60875C (en) 1982-04-13
FI60875B (en) 1981-12-31
DE2616984A1 (en) 1977-10-20
FR2348222A1 (en) 1977-11-10
CH630643A5 (en) 1982-06-30
DK168577A (en) 1977-10-18
IL51883A0 (en) 1977-06-30
NO146747B (en) 1982-08-23
IT1075832B (en) 1985-04-22
BE853711A (en) 1977-10-18
CA1101847A (en) 1981-05-26
CH632091A5 (en) 1982-09-15
IE44824L (en) 1977-10-17

Similar Documents

Publication Publication Date Title
LV10538A (en) Influence of immunologically binding agent on biological fluid and diagnostic agent
ES398372A1 (en) Process for the detection and determination of specific binding proteins and their corresponding bindable substances
DK97189A (en) immobilization
ATE15945T1 (en) PROCEDURE FOR DETECTING HAEMOGLOBIN IN FAEZES.
GB1498081A (en) Covalently bound biological substances to plastic materials and use in radioassay
ES457714A1 (en) Process for the isolation of a placentaspecificglycoprotein
ES454276A1 (en) Pregnancy test device
AU8317482A (en) Assay of antibodies to soluble antigens
DE3485289D1 (en) MONOCLONAL ANTIBODY VERSION FOR DIAGNOSTIC USE.
ES8604694A1 (en) Iodothyronine immunoassays employing HMS as TBP blocking agent.
NO881904L (en) PROCEDURE FOR SELECTIVE IMMUNOLOGICAL DETERMINATION OF INTACT PROCOLLAGEN PEPTID (TYPE III) AND PROCOLLAGEN (TYPE III) IN BODY LIQUID, AND AGENT FOR ITS IMPLEMENTATION.
DK256387A (en) IMMUNE DETERMINATION METHOD AND EQUIPMENT
ATE124706T1 (en) METHOD FOR ISOLATION OF BASAL MEMBRANE PROTEINS FROM HUMAN AND ANIMAL TISSUES.
GB1151608A (en) A Method for Determining Vitamin B12
GB2007362A (en) Method of preparing a device for use in immunoassay
FR2385099A1 (en) Rapid determn. of antigens and antibodies - by marking with enzyme, complex formation on a support and acid elution
JPS5378665A (en) Method of refining valuable substance contained liquid
ES446939A1 (en) Process for the enrichment of pregnancy specific -glycoprrotein
DE3477516D1 (en) Method and reagent for the direct detection of an analyte after the specific elimination of colloidal particles in aqueous solutions of biological origin
ES8404513A1 (en) Improved specimen slide for occult blood testing.
DE3781808T2 (en) DIAGNOSTIC TEST PROCEDURE FOR PIG DYSENTERIES.
ES2002578A6 (en) A process for the preparation of diagnostic reagents.
KR840005343A (en) A method for separating or purifying sleep-promoting factors from biological media by the reaction of antigen-antibodies
FR2324005A1 (en) Analytical method, esp. for thyroxine, using proteolytic enzyme - to release active component from binding protein
JPS5243492A (en) Densitometer